FDA approves 1st drug to treat postpartum depression

The FDA approved Zulresso, the first treatment specifically intended for women with postpartum depression.

Zulresso is also the first drug developed by and approved from Sage Therapeutics, a Cambridge, Mass.-based biotech.

Postpartum depression disorder, which affects approximately 400,000 women each year, is a major depressive episode that occurs following childbirth.

Zulresso, also known as brexanolone, is designed to work faster than other antidepressants and is administered intravenously.

Sage told The Wall Street Journal that it will cost $7,450 per vial, or $34,000 for an average course of therapy, before any discounts.

The drug will also need to be administered in a hospital or clinic.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars